Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma

BACKGROUND: This phase II study assessed the response rate and toxicity profile of weekly paclitaxel and capecitabine in patients with metastatic or recurrent squamous cell carcinoma of the esophagus (SCCE) METHODS: Patients with histologically confirmed SCCE were treated with paclitaxel 80 mg/m(2 )...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Yun, Tak, Han, Ji-Youn, Lee, Jin Soo, Choi, Hyun Lee, Kim, Hyae Young, Nam, Byung-Ho, Kim, Heung Tae
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2011
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3176247/
https://ncbi.nlm.nih.gov/pubmed/21888637
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-11-385
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak